Our findings are consistent with previous reports of the ability of IGF-1 infusion to reverse the anticancer effects of CR in models of mammary, pancreas, bladder, and hematopoietic cancers [10, 23, 48, 49]. The gene discussed is IGF1; the disease is hematopoietic and lymphoid cell neoplasm.